Friday, October 6, 2017: 2:00 PM-3:30 PM
Tracks: Adult ID, HIV-STD-TB, Trainee
Moderators: Rajesh Gandhi, MD, FIDSA, Massachusetts General Hospital and Aadia Rana, MD, UAB
Week 48 results of EMERALD: A Phase 3, randomized, non-inferiority study evaluating the efficacy and safety of switching from boosted-protease inhibitors (bPI) plus emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) regimens to the once daily (QD), single-tablet regimen (STR) of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in virologically-suppressed, HIV-1-infected adults
CME Credits: No CME credit is offered for this session.
See more of: Oral Abstract Session